FDA says no to Vanda (NASDAQ: VNDA) HETLIOZ jet lag application
Rhea-AI Filing Summary
Vanda Pharmaceuticals reports that the U.S. Food and Drug Administration has completed an expedited re-review of its supplemental New Drug Application for HETLIOZ as a treatment for jet lag disorder and concluded the application cannot be approved in its current form. This re-review was conducted under a previously announced collaborative framework between Vanda and the FDA, with a target date of January 7, 2026. The decision represents a setback for Vanda’s efforts to add jet lag disorder as a new indication for HETLIOZ. Vanda issued a press release on January 8, 2026, and has attached the full text as an exhibit.
Positive
- None.
Negative
- FDA concluded Vanda’s HETLIOZ sNDA for jet lag disorder cannot be approved in its current form after expedited re-review.
Insights
FDA declined to approve Vanda’s HETLIOZ jet lag sNDA after re-review.
Vanda Pharmaceuticals describes an FDA decision that its supplemental New Drug Application for HETLIOZ to treat jet lag disorder "cannot be approved in its current form" following an expedited re-review. This follows an earlier collaborative framework where the FDA agreed to complete that re-review by January 7, 2026, so the decision effectively closes out that process without approval for the proposed indication.
For Vanda, this outcome is a clear regulatory setback for expanding HETLIOZ beyond its existing uses into jet lag disorder. The disclosure notes that the company issued a press release on January 8, 2026, and attached it as an exhibit, which suggests further detail on the company’s response and next steps may be contained there. The actual commercial and pipeline impact will depend on any future regulatory strategy Vanda may pursue, which is not described in this excerpt.
8-K Event Classification
